A study of vedolizumab for the treatment of moderate to severe active ulcerative colitis (UC)
Phase of Trial: Phase I/II
Latest Information Update: 16 May 2017
At a glance
- Drugs Vedolizumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- 16 May 2017 New trial record
- 08 May 2017 Results published in the Takeda Pharmaceuticals media release.
- 08 May 2017 According to a Takeda Pharmaceutical media release, cohort analysis of this trial from the U.S. VICTORY (Vedolizumab for Health OuTComes in InflammatORY Bowel Diseases) consortium was presented at the 2017 Digestive Disease Week (DDW) annual scientific meeting.